28.10
0.34 (1.22%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Palvella Therapeutics, Inc. | Bearish | - |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.63 |
|
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. It is developing a broad pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Palvella’s lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 17.50% |
| % Held by Institutions | 37.21% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Adams Street Partners Llc | 31 Dec 2024 | 409,666 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 50.00 (Scotiabank, 77.94%) | Buy |
| Median | 44.50 (58.36%) | |
| Low | 38.00 (HC Wainwright & Co., 35.23%) | Buy |
| Average | 43.50 (54.80%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 23.57 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 01 Apr 2025 | 38.00 (35.23%) | Buy | 28.10 |
| 11 Feb 2025 | 38.00 (35.23%) | Buy | 16.15 | |
| Stifel | 26 Mar 2025 | 45.00 (60.14%) | Buy | 27.93 |
| Jones Trading | 25 Mar 2025 | 45.00 (60.14%) | Buy | 27.27 |
| Scotiabank | 07 Mar 2025 | 50.00 (77.94%) | Buy | 24.55 |
| Canaccord Genuity | 26 Feb 2025 | 39.00 (38.79%) | Buy | 18.80 |
| 20 Feb 2025 | 39.00 (38.79%) | Buy | 19.00 | |
| TD Cowen | 05 Feb 2025 | 44.00 (56.58%) | Buy | 14.76 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |